Literature DB >> 11144927

Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia.

R N Miranda1, R C Briggs, M C Kinney, P A Veno, R D Hammer, J B Cousar.   

Abstract

Mantle cell lymphoma (MCL) is more aggressive when compared with other lymphomas composed of small, mature B lymphocytes. Cyclin D1 is overexpressed in MCL as a result of the translocation t(11;14)(q13;q32). Cyclin D1 immunohistochemistry in fixed, paraffin-embedded tissue contributes to the precise and reproducible diagnosis of MCL without the requirement of fresh tissue. However, its use in bone marrow biopsies is not well established. In addition, increased levels of cyclin D1 mRNA have been found in hairy cell leukemia but have not consistently been detected by immunohistochemistry. We used a polyclonal antibody and heat-induced antigen retrieval conditions to evaluate 73 fixed, paraffin-embedded bone marrow, spleen, and lymph node specimens with small B-cell infiltrates, obtained from 55 patients. Cyclin D1 was overexpressed in 13/13 specimens of MCL (usually strong, diffuse reactivity in most tumor cells) and in 14/14 specimens of hairy cell leukemia (usually weak, in a subpopulation of tumor cells). No reactivity was detected in five cases of B-chronic lymphocytic leukemia; five cases of splenic marginal zone lymphoma; six cases of nodal marginal zone cell lymphoma; two cases of gastric marginal zone cell lymphoma; or ten benign lymphoid infiltrates in bone marrow, spleen, or lymph nodes. In summary, although the total number of studied cases is small and a larger series of cases may be required to confirm our data, we present optimized immunohistochemical conditions for cyclin D1 in fixed, paraffin-embedded tissue that can be useful in distinguishing MCL and hairy cell leukemia from other small B-cell neoplasms and reactive lymphoid infiltrates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144927     DOI: 10.1038/modpathol.3880239

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

1.  Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma.

Authors:  Habil Zare; Ali Bashashati; Robert Kridel; Nima Aghaeepour; Gholamreza Haffari; Joseph M Connors; Randy D Gascoyne; Arvind Gupta; Ryan R Brinkman; Andrew P Weng
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

2.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

3.  Fluorescence PCR quantification of cyclin D1 expression.

Authors:  Kojo S J Elenitoba-Johnson; Sandra D Bohling; Stephen D Jenson; Zhaosheng Lin; Kimberly A Monnin; Megan S Lim
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

4.  A comprehensive immunophenotypic marker analysis of hairy cell leukemia in paraffin-embedded bone marrow trephine biopsies--a tissue microarray study.

Authors:  Judit Tóth-Lipták; Klára Piukovics; Zita Borbényi; Judit Demeter; Enikő Bagdi; László Krenács
Journal:  Pathol Oncol Res       Date:  2014-06-06       Impact factor: 3.201

5.  The subcellular distribution of cyclin-D1 and cyclin-D3 within human islet cells varies according to the status of the pancreas donor.

Authors:  Kazuto Taniguchi; Mark A Russell; Sarah J Richardson; Noel G Morgan
Journal:  Diabetologia       Date:  2015-06-09       Impact factor: 10.122

6.  Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes.

Authors:  László Krenács; Judit Tóth-Lipták; Judit Demeter; Klára Piukovics; Zita Borbényi; Péter Gogolák; Eszter Sári; Enikő Bagdi
Journal:  Virchows Arch       Date:  2013-10-05       Impact factor: 4.064

7.  Protective effect of indomethacin in renal ischemia-reperfusion injury in mice.

Authors:  Sheng-hong Zhu; Li-jia Zhou; Hong Jiang; Rong-jun Chen; Chuan Lin; Shi Feng; Juan Jin; Jiang-hua Chen; Jian-yong Wu
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

8.  Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma.

Authors:  Michael Dictor; Sara Ek; Maria Sundberg; Janina Warenholt; Czabafy György; Sandra Sernbo; Elin Gustavsson; Waleed Abu-Alsoud; Torkel Wadström; Carl Borrebaeck
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

9.  BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Authors:  Valentina Pettirossi; Alessia Santi; Elisa Imperi; Guido Russo; Alessandra Pucciarini; Barbara Bigerna; Gianluca Schiavoni; Elisabetta Fortini; Ariele Spanhol-Rosseto; Paolo Sportoletti; Roberta Mannucci; Maria Paola Martelli; Ludger Klein-Hitpass; Brunangelo Falini; Enrico Tiacci
Journal:  Blood       Date:  2014-12-05       Impact factor: 22.113

10.  A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas.

Authors:  Kartik M Mani; Celine Lefebvre; Kai Wang; Wei Keat Lim; Katia Basso; Riccardo Dalla-Favera; Andrea Califano
Journal:  Mol Syst Biol       Date:  2008-02-12       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.